Background: The combination of 5-fluorouracil (5-FU) and cisplatin has shown great activity in many different types of tumour with an in vitro synergistic effect between 5-FU and cisplatin. A phase II study of 5-FU plus cisplatin was performed in 25 previously untreated patients with inoperable locally advanced or metastatic biliary tract carcinoma.
Introduction
Most reports of chemotherapy for cancers of the biliary system involve very small numbers of patients. Response rates appear to be similar to those for advanced carcinomas of the gallbladder, bile duct and intrahepatic cholangiocarcinoma. For single-agent systemic chemotherapy, the objective response rates vary from 10% to 25% in the series including 15 or more patients [1, 2] . 5-fluorouracil (5-FU) was the most promising agent in these studies [1] . Multiagent systemic chemotherapy does not seem to increase the response rate: the combination regimens FAM: 5-FU + adriamycin + mitomycin C, and 5-FU plus methyl-CCNU yielded poor results: 29% and 10%, respectively [1, 3] . Cisplatin as a single agent chemotherapy is not effective in this tumour [4] , but because the combination of 5-FU and cisplatin has shown great activity in many different types of tumour with an in vitro synergistic effect between 5-FU and cisplatin [5] , we decided to assess the efficacy of this treatment in biliary tract cancer.
Patients and methods
From January 1991 to December 1994, 25 consecutive patients were included in this phase II study. Eligibility criteria were the presence of histologically proven adenocarcinoma of the biliary tract with evidence of metastatic disease or unresectable local recurrence and no previous chemotherapy. Patients had to have a performance status (PS) <3 (WHO grade), age <75 years, an adequate blood count (white blood cell count >4000/ml, platelets > 100,000/ml), no signs of renal or hepatic failure (serum creatinine <135 umol/1, prothrombin time > 75%) and no other malignancy. All patients had to have measurable disease on computed tomography (CT)-scan. All patients gave their informed consent.
Pre-treatment evaluation included a complete physical examination, an abdominal ultrasound, an abdominal CTscan and a thoracic CT scan if they had lung metastases. Renal function tests, hepatic enzymes, serum lactic dehydrogenase (LDH), carcino-embryonic antigen (CEA) and carbohydrate antigen assays (CA 19-9) were performed before each cycle. Complete blood and platelet counts were performed every week to assess haematological toxicity.
The chemotherapy regimen was 5-FU: 1 g/m 2 /day in continuous intravenous (i.v.) infusion for five consecutive days, and cisplatin: 100 mg/m 2 /day on day 2 in a one-hour infusion with standard hyperhydration. Cycles were repeated every four weeks according to haematological, digestive and renal tolerance. Treatment continued until progression, intolerable toxicity or elective withdrawal from the trial. All of the patients were given prophylactic antiemetic treatment consisting of 5HT3 antagonists for the first seven patients and a combination of 5HT3 antagonists and dexamethasone for the remaining 18. The 5-FU dosage was reduced in instances of stomatitis, diarrhoea, neutropenia Tumour size was measured by computed tomography (CT), and tumour response was assessed every eight weeks after the start of the chemotherapy. Toxicity and response were classified according to World Health Organisation (WHO) criteria [6] . We denned response duration as the period between the onset of response and the day thereafter on which progressive disease was first noted. The onset o[ response was defined as the time when the criteria for a particular response were first met (i.e., reduction 3=50% for partial response (PR), and complete disappearance for complete response (RQ). Survival was calculated from the start of chemotherapy using the Kaplan-Meier method.
Results
Twenty-five patients (11 with gallbladder carcinoma, 14 with intrahepatic or extrahepatic cholangiocarcinoma) were entered into the study. The main patient characteristics before chemotherapy are summarised in Table 1 .
The 25 patients were evaluable for toxicity, but only 24 patients were evaluable for response (one patient ineligible due to diffuse invasion of the biliary tree without measurable lesions). The median number of cycles was four (range 1-6).
Toxicity (Table 2) Haematological side effects were usually mild. However, six patients experienced grade 3 neutropaenia and one a grade 4 neutropaenia. Neutropaenia was febrile in
, but all of them were able to continue treatment despite this toxic effect. One patient developed grade 2 renal toxicity which precluded the administration of cisplatin after four cycles. Two patients showed severe peripheral neuropathy after four and five cycles, so treatment was discontinued. One patient had moderate ototoxicity after six cycles of chemotherapy. There were no toxic deaths.
Response and survival
Of the 25 evaluable patients, six had partial remissions, 12 had no change, and seven had progressive disease, leading to an overall response rate of six out of 24 (25%; 95% confidence interval 6%-42%). The response rate was: 15% in cholangiocarcinomas and 36% in gallbladder cancer patients (NS). The median duration of response was five months (one complete response after chemotherapy + radiotherapy, duration = 5.5+ years). The median survival was 10 months, the one-year survival: 33% ± 6% (Figure 1) . In three patients, the residual lesions were treated by radiotherapy. One of these patients with an inoperable locoregional recurrence who showed a partial response after six cycles of chemotherapy improved to a complete response after irradiation. This patient is still in complete remission and good health six years after the treatment.
Discussion
We observed in this series a 25% response rate with the combination of 5-FU and cisplatin in patients with biliary tract carcinoma. This series is a group of 25 consecutive patients with advanced or metastatic disease and these results are promising. This is the second largest single series of biliary tract tumours treated with a uniform chemotherapeutic regimen. The median survival of 10 months is not too short. Figure 1 . Overall survival of the 25 patients who were treated by chemotherapy for advanced biliary tract cancer.
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Treatment toxicity was manageable and not radically different from the toxicity observed in other types of tumour with the same schedule [5, 7] . Nausea/vomiting was the main toxicity, but all patients for whom it was considered effective were able to continue the treatment.
A few studies have tested chemotherapy in biliary tract carcinoma. Monochemotherapy yielded disappointing results, with objective response rates ranging from 5% to 20%. Mitomycin C, which seemed relatively active in the past, was assessed by the EORTC. The treatment's activity was evaluated using recent and precise rules: of 30 patients, three had partial remissions, for an overall response rate of 10% [2] . Paclitaxel does not have promising results in biliary tract carcinoma: no complete or partial responses were noted in 13 patients although two patients achieved minor responses [8] . Two phase II studies compared 5-FU alone to polychemotherapy. In the first study, the regimens compared to 5-FU alone were 5-FU plus streptozotocin and 5-FU plus methyl-CCNU [1] . The comparison did not show an advantage for the polychemotherapy, which had increased toxic effects without clear benefit in terms of responses. The second randomised trial gives comparable results disproving the hypothesis that 5-FU plus adriamycin plus mitomycin C are superior to 5-FU alone [9] . In a recent phase II study the combination of 5-FU, epirubicin and methotrexate yielded no responses [10] . Two recent phase II studies have shown more promising results. The first one combined 5-FU and subcutaneous recombinant human interferon-oc-2b in patients with measurable cancer of the biliary tract. The objective response rate was 34% in this study and the median survival 12 months, closely similar to the results of our study. Grade 3-4 toxic effects were frequent: neutropenia 14%, stomatitis: 20%, asthenia: 6%. When compared to our schedule, this treatment seems to have a similar efficacy but a higher toxicity and cost [11] . A second recent phase II study investigated the efficacy of the ECF regimen which combined low-dose 5-FU continuous infusion plus epirubicin plus cisplatin. Eight of the 20 evaluable patients responded; the median duration of response was 10 months and the median survival was 11 months [12] . The regimen was relatively well tolerated with 16% grade 3-4 leukopenia and 19% thrombocytopaenia, but grade 3 alopecia was observed in 31% of the patients. The 5-FU continuous infusion does not seem to decrease quality of life in patients with gastric cancer [13] . However, it makes the treatment more onerous for the patient and more expansive than the classical five-day/5-FU cisplatin schedule we chose to test in these patients with short life expectancy.
These recent optimistic data are supported by the results of the only phase III study performed in this area. Glimelius et al. [14] randomised 90 patients with pancreatic or biliary cancer (43 and 37, respectively) to either chemotherapy in addition to best supportive care or to best supportive care. Chemotherapy was either sequential 5-FU/leucovorin combined with etoposide or, in elderly and poor-performance-status patients, the same regimen without etoposide. The overall conclusion was clear: chemotherapy improves the survival of such patients without impairing their quality of life. However, when only the patients with biliary tract cancer were considered the results were no longer statistically significant although they reached the same absolute value.
It must be pointed out that one of our patients had a very extensive local disease recurrence which was not surgically treatable and difficult to irradiate. This patient had a very rapid and dramatic response to chemotherapy which rendered him ready for radiotherapy after six treatment cycles. With a six-year follow-up she remains disease-free.
In conclusion: 5-FU plus cisplatin is an active chemotherapy in metastatic or inoperable biliary tract carcinoma. This widely used schedule has a manageable toxicity, and should be considered for further investigation.
